Fresenius details pay structure in new annual report, shares stay in focus for DAX investors

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 14:01.

Fresenius SE & Co. KGaA (DE0005785604) has published its most recent annual report with a detailed section on management and employee compensation, offering investors a fresh look at pay structures across the group. The DAX-listed healthcare company remains a core name for Frankfurt investors as it rebuilds its portfolio around Helios hospitals and Kabi generic medicines, according to its latest filings and investor materials Fresenius financial reports and presentations.

What the new report shows on compensation

The newly published annual report sets out how Fresenius structures fixed salaries, variable bonuses and long-term incentives for its management board, supervisory board and key executives, including the Chief Executive Officer and the Chief Financial Officer. The company explains how short-term bonuses are linked to financial metrics such as net income, EBIT and cash flow, and how multi-year share-based components are used to align managers with shareholder interests Fresenius annual report 2023.

Alongside executive compensation, the report also discloses the total personnel expenses for the roughly 190,000 employees worldwide, including wages, salaries, social security contributions, pension costs and share-based payments. Fresenius outlines how these costs are distributed across its main segments, with Helios hospitals and Kabi accounting for the bulk of the group payroll, reflecting their labor-intensive business models and large global workforces.

How compensation ties into Fresenius strategy

Fresenius uses the compensation report to underline its strategic priorities after the spin-off of dialysis specialist Fresenius Medical Care and the sale of various non-core assets. Variable pay for the management board is increasingly tied to profitability in the remaining core segments, return on capital employed and deleveraging, as the group works to strengthen its balance sheet and protect its investment-grade rating, according to company statements and analyst commentary Handelsblatt coverage of the Fresenius restructuring.

In addition, Fresenius sets non-financial targets in areas such as quality of care, patient safety and employee engagement, which can influence variable compensation outcomes for management and selected leadership groups. The report notes that these qualitative measures play a supporting role alongside core financial indicators, reflecting the companys position in regulated healthcare markets in Germany, Spain, Latin America and other regions where service quality is crucial for long-term contracts.

How Fresenius makes its money

Fresenius generates most of its revenue through its Helios hospital network and its Kabi business for generic intravenous drugs, clinical nutrition and infusion technologies. In Germany and Spain, Helios operates large acute care and specialist clinics, while Kabi supplies hospitals and clinics worldwide with generic oncology drugs, anesthesia products and parenteral nutrition solutions for critically ill patients. Fresenius business segment overview

Where the stock trades today

Fresenius shares are listed on Xetra in Frankfurt, where the stock most recently changed hands at around 30 euros in late June 2026, according to exchange data and market quotes.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.